Profound Medical (PROF) Expected to Announce Earnings on Thursday

Profound Medical (NASDAQ:PROF) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Profound Medical to announce earnings of ($0.22) per share and revenue of $4.75 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.05. Profound Medical had a negative return on equity of 78.88% and a negative net margin of 206.76%.The business had revenue of $5.34 million for the quarter, compared to the consensus estimate of $4.85 million. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Price Performance

Profound Medical stock opened at $8.41 on Wednesday. The firm has a 50-day moving average of $6.93 and a 200-day moving average of $6.81. Profound Medical has a one year low of $3.76 and a one year high of $8.95. The company has a market cap of $305.62 million, a price-to-earnings ratio of -6.78 and a beta of 0.73.

Wall Street Analyst Weigh In

PROF has been the topic of several research analyst reports. Raymond James Financial raised shares of Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research report on Monday, July 27th. Weiss Ratings raised Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Profound Medical currently has an average rating of “Moderate Buy” and an average price target of $11.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its position in shares of Profound Medical by 56.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after purchasing an additional 6,787 shares during the period. National Bank of Canada FI boosted its holdings in shares of Profound Medical by 7.3% during the 3rd quarter. National Bank of Canada FI now owns 172,883 shares of the company’s stock valued at $845,000 after purchasing an additional 11,704 shares during the last quarter. Royal Bank of Canada grew its position in shares of Profound Medical by 3.5% during the first quarter. Royal Bank of Canada now owns 435,997 shares of the company’s stock valued at $2,537,000 after purchasing an additional 14,795 shares in the last quarter. Bank of America Corp DE grew its position in shares of Profound Medical by 14.3% during the third quarter. Bank of America Corp DE now owns 200,160 shares of the company’s stock valued at $979,000 after purchasing an additional 24,974 shares in the last quarter. Finally, Corsair Capital Management L.P. bought a new stake in shares of Profound Medical in the fourth quarter worth about $208,000. 47.86% of the stock is owned by institutional investors.

About Profound Medical

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.